Epithalon vs SS-31

Epithalon

Epithalon (also known as Epitalon or epithalamin) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology in Russia. Its primary mechanism of action involves activation of telomerase, the enzyme responsible for adding telomeric repeats (TTAGGG) to chromosome ends, thereby counteracting the progressive telomere shortening associated with cellular aging. Published research by Khavinson and colleagues (Bulletin of Experimental Biology and Medicine, 2003) demonstrated that epithalon increased telomerase activity in human somatic cells and extended the replicative lifespan of fibroblast cultures beyond the Hayflick limit. In animal studies, chronic epithalon use in aging rats was associated with increased lifespan and restoration of melatonin secretion rhythms from the pineal gland, which naturally declines with age (Anisimov et al., Mechanisms of Ageing and Development, 2003). The peptide also appears to modulate expression of genes involved in antioxidant defense and circadian rhythm regulation. Compared to other telomerase activators such as TA-65 (a small molecule derived from astragalus), epithalon is a direct peptide bioregulator with a well-characterized tetrapeptide sequence. Research also suggests potential effects on retinal health, with studies indicating photoreceptor preservation in aging retinal models. Store lyophilized powder at -20C protected from moisture; reconstitute with bacteriostatic water and refrigerate at 2-8C for up to 21 days. Epithalon is studied by gerontology research centers, telomere biology laboratories, and chronobiology departments investigating age-related decline in pineal gland function.

SS-31

SS-31, also known as Elamipretide or Bendavia (D-Arg-Dmt-Lys-Phe-NH2), is a cell-permeable tetrapeptide that selectively concentrates in the inner mitochondrial membrane. Its primary mechanism involves binding to cardiolipin, a phospholipid unique to mitochondrial membranes that is essential for electron transport chain organization and ATP synthase function. By stabilizing cardiolipin microdomains, SS-31 modulates electron transfer between complexes III and IV, reduces electron leak, and limits reactive oxygen species (ROS) generation at the source. Research by Szeto (2006) published in AAPS Journal described SS-31's unique mitochondria-targeting pharmacology, demonstrating 5,000-fold concentration in mitochondria relative to cytoplasm within minutes of exposure. Clinical studies published in Circulation: Heart Failure by Daubert et al. showed that SS-31 improved left ventricular volumes in heart failure patients during a Phase 1/2 trial. Preclinical work in the Journal of the American Society of Nephrology demonstrated renal protective effects in ischemia-reperfusion injury models, with SS-31 preserving mitochondrial cristae structure and reducing tubular cell death. Compared to general antioxidants like CoQ10 or vitamin E, SS-31 targets ROS production at the mitochondrial source rather than scavenging free radicals after they are formed. This upstream approach is considered more efficient by researchers. MitoQ, another mitochondria-targeted compound, accumulates via membrane potential rather than cardiolipin binding, giving SS-31 a distinct pharmacological profile, particularly in depolarized or damaged mitochondria. Store lyophilized SS-31 at -20°C in a desiccated, light-protected environment. Reconstitute with bacteriostatic water and store at 2-8°C, using within 4 weeks. SS-31 is actively investigated by mitochondrial biologists, cardiologists studying heart failure, nephrologists, and aging researchers examining mitochondrial dysfunction as a driver of age-related disease.

Frequently Asked Questions